Want to see AU:CU6 full AI Analyst Report?
Top Page
Clarity Pharmaceuticals Ltd.
(Sydney:CU6)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$1.50
â–¼(-40.00% Downside)
Action:Reiterated
Date:10/16/26
The score is driven primarily by weak financial performance—zero revenue in 2026, widening losses, and persistent negative free cash flow with elevated cash-burn risk—partly mitigated by a debt-free balance sheet. Technicals add pressure with a clear downtrend across key moving averages and negative MACD, despite oversold readings. Valuation is constrained by a negative P/E due to losses and no dividend yield data.
Positive Factors
Debt-free balance sheet
No reported debt across all periods lowers solvency and refinancing exposure, giving Clarity greater flexibility to fund clinical development and absorb operating volatility. This is a durable balance-sheet advantage while the company remains pre-profit and dependent on continued investment.
Negative Factors
Revenue disruption
Revenue fell to zero in 2026 after a modest 2025 decline, marking a sharp reversal in top-line momentum. This removes current operating revenue to support development and makes near-term business scale and earnings visibility highly dependent on restoring revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
No reported debt across all periods lowers solvency and refinancing exposure, giving Clarity greater flexibility to fund clinical development and absorb operating volatility. This is a durable balance-sheet advantage while the company remains pre-profit and dependent on continued investment.
Read all positive factors
Clarity Pharmaceuticals Ltd. (CU6) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$583.87M
Dividend YieldN/A
Average Volume (3M)2.40M
Price to Earnings (P/E)―
Beta (1Y)2.48
Revenue GrowthN/A
EPS Growth-44.83%
CountryAU
Employees100
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.29
Shares Outstanding373,081,240
10 Day Avg. Volume3,373,395
30 Day Avg. Volume2,400,360
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.23
Price to Sales (P/S)0.00
P/FCF Ratio-8.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$7.39Price Target Upside195.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.32
Revenue Forecast (FY)AU$7.93M
Clarity Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranost...
Clarity Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 9.46M | 11.51M | 9.80M | 6.46M |
| Gross Profit | -283.53K | 9.46M | 11.51M | 9.70M | 6.41M |
| EBITDA | -118.62M | -68.91M | -44.65M | -34.20M | -30.15M |
| Net Income | -107.14M | -64.30M | -42.32M | -24.60M | -23.75M |
Balance Sheet | |||||
| Total Assets | 199.06M | 101.17M | 154.63M | 76.90M | 99.82M |
| Cash, Cash Equivalents and Short-Term Investments | 178.25M | 84.12M | 136.51M | 65.01M | 92.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 12.96M | 10.94M | 8.33M | 7.72M | 7.59M |
| Stockholders Equity | 186.11M | 90.23M | 146.30M | 69.18M | 92.24M |
Cash Flow | |||||
| Free Cash Flow | -92.85M | -54.95M | -43.74M | -27.55M | -13.53M |
| Operating Cash Flow | -92.55M | -54.77M | -43.24M | -27.50M | -13.31M |
| Investing Cash Flow | -84.92M | 51.99M | -55.31M | 3.15M | -26.71M |
| Financing Cash Flow | 192.96M | 2.21M | 115.21M | 231.58K | 86.93M |
Clarity Pharmaceuticals Ltd. Technical Analysis
Negative
2.50
Price Trends
2.08
Negative
2.22
Negative
2.65
Negative
Market Momentum
-0.15
Positive
28.80
Positive
13.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CU6, the sentiment is Negative. The current price of 2.5 is above the 20-day moving average (MA) of 1.82, above the 50-day MA of 2.08, and below the 200-day MA of 2.65, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 28.80 is Positive, neither overbought nor oversold. The STOCH value of 13.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CU6.
Clarity Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$4.44B | 100.44 | 7.24% | ― | 26.66% | 179.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$35.38M | -0.46 | -98.86% | ― | ― | -27.73% | |
43 Neutral | AU$220.68M | -26.90 | -42.35% | ― | 145.32% | 25.75% | |
42 Neutral | AU$583.87M | -5.75 | -51.15% | ― | ― | -44.83% | |
42 Neutral | AU$297.04M | -25.04 | -36.95% | ― | ― | -125.09% | |
42 Neutral | AU$21.20M | -0.26 | -144.24% | ― | -23.82% | 12.36% |
* Healthcare Sector Average
AU:CU6
Clarity Pharmaceuticals Ltd.
1.57
-3.05
-66.05%
AU:IMM
Immutep Ltd
0.02
-0.28
-92.00%
AU:SPL
Starpharma Holdings Limited
0.46
0.11
29.58%
AU:TLX
Telix Pharmaceuticals
13.06
-3.11
-19.23%
AU:RAC
Race Oncology Ltd.
1.52
-1.92
-55.83%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.01
-58.33%
Clarity Pharmaceuticals Ltd. Corporate Events
Clarity Pharmaceuticals Sets Date and Details for 2026 AGM
Oct 22, 2026
Clarity Pharmaceuticals has issued a Notice of Meeting for its 2026 Annual General Meeting, scheduled for 25 November 2026 at the National Innovation Centre in Eveleigh, Sydney. The meeting will begin at 10:00am Sydney time and will cover the comp...
State Street Units Exit Substantial Holder Position in Clarity Pharmaceuticals
Oct 20, 2026
State Street Corporation and several of its global asset management subsidiaries have filed a notice that they have ceased to be substantial shareholders in Clarity Pharmaceuticals Ltd as of 16 October 2026. The change reflects a reduction in thei...
Clarity Hits SECuRE Recruitment Milestone as Prostate Cancer Theranostic Data Build
Oct 7, 2026
Clarity Pharmaceuticals has reached the recruitment target for the Main Group of the Cohort Expansion phase in its Phase I/IIa SECuRE trial, enrolling 16 patients with metastatic castration-resistant prostate cancer to receive up to six cycles of ...
Clarity Pharmaceuticals Updates Corporate Governance Framework for 2026
Sep 30, 2026
Clarity Pharmaceuticals has released an updated Corporate Governance Statement for the year ending 30 June 2026, prepared in line with the ASX Corporate Governance Principles and Recommendations. The statement, approved by the board as at 30 Septe...
Clarity Pharmaceuticals Lodges ASX Governance Appendix 4G for FY2026
Sep 30, 2026
Clarity Pharmaceuticals has lodged its Appendix 4G with the ASX for the financial year ended 30 June 2026, directing investors to its updated corporate governance statement hosted on its website. The filing confirms the board’s approval of i...
Clarity Pharmaceuticals Details Strategy and Progress in 2026 Annual Report
Sep 30, 2026
Clarity Pharmaceuticals has released its 2026 annual report, outlining corporate, financial, clinical and regulatory developments across its radiopharmaceutical portfolio. The report highlights product updates, clinical milestones and discovery pr...
State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Sep 24, 2026
State Street Corporation, through a group of global subsidiaries including State Street Global Advisors and affiliated trust and funds management entities, has filed notice that it has ceased to be a substantial holder in Clarity Pharmaceuticals L...
Clarity Pharmaceuticals Sets AGM Date as It Advances Cancer-Focused Radiopharmaceutical Strategy
Sep 21, 2026
Clarity Pharmaceuticals Ltd., listed on the ASX under ticker CU6, is a clinical-stage radiopharmaceutical company focused on treating serious diseases, particularly cancers. It is a leader in developing innovative Targeted Copper Theranostics buil...
Clarity Pharmaceuticals Lifts Revenue but Posts Wider Loss in FY26 Preliminary Results
Aug 27, 2026
Clarity Pharmaceuticals has released its Appendix 4E preliminary final report for the year ended 30 June 2026, showing revenue from ordinary activities rising 68% to $8.0 million. Despite the top-line growth, the company’s loss after tax wid...
State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Aug 12, 2026
State Street Corporation and several of its global asset management subsidiaries have lodged a notice that they have ceased to be substantial holders in Clarity Pharmaceuticals Ltd as of 10 August 2026. The change reflects an adjustment in their r...
State Street Group Ceases Substantial Holding in Clarity Pharmaceuticals
Aug 6, 2026
State Street Corporation and several of its asset management subsidiaries have lodged a notice that they have ceased to be a substantial holder in Clarity Pharmaceuticals Ltd. This change in relevant interest, recorded under section 671B of the Co...
Clarity Highlights SAR-bisPSMA Pipeline and Emphasises High-Risk, Early-Stage Profile
Aug 6, 2026
Clarity Pharmaceuticals used the Bioshares Biotech Summit to highlight its Australian-developed SAR-bisPSMA radiopharmaceutical platform and broader investigational pipeline, all of which remain unapproved by regulators such as the FDA and TGA. Th...
Clarity Posts Strong 67Cu-SAR-bisPSMA Data in SECuRE Prostate Cancer Trial
Aug 5, 2026
Clarity Pharmaceuticals has reported encouraging preliminary safety and efficacy data from the 8 GBq dose level of its 67Cu-SAR-bisPSMA therapy in the SECuRE trial for advanced prostate cancer. Among 19 participants, most of whom had bone metastas...
Clarity Pharmaceuticals Bolsters Cash, Manufacturing and Governance Ahead of Commercial Launch
Jul 31, 2026
Clarity Pharmaceuticals ended the June 2026 quarter with a cash balance of $178.3 million, more than 60% held in U.S. dollars to hedge its substantial American clinical, operational and commercial spending, though the stronger Australian dollar pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.